Cargando…
Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab
Further understanding of psoriasis pathogenesis has led to the development of effective biologic medications. Guselkumab (GUS) is a subcutaneously administered monoclonal antibody that targets the p19 cytokine subunit in IL-23 and IL-39 and is US Food and Drug Administration (FDA) approved for the t...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110646/ https://www.ncbi.nlm.nih.gov/pubmed/30174431 http://dx.doi.org/10.2147/TCRM.S177127 |